Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has...

Full description

Bibliographic Details
Main Authors: Francesco Bartoli, Ilaria Riboldi, Bianca Bachi, Angela Calabrese, Federico Moretti, Cristina Crocamo, Giuseppe Carrà
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
Cannabidiol
Δ-9-tetrahydrocannabinol
schizophrenia
psychotic disorders
cannabis use disorder
dual diagnosis
Online Access:https://www.mdpi.com/2077-0383/10/6/1303

Similar Items

Similar Items